Rob Schwartzman received his B.S. in chemistry from Rensselaer Polytechnic Institute, and Ph.D. in pharmacology from the University of North Carolina – Chapel Hill. His doctoral research focused on steroid-induced apoptosis in thymocytes. He conducted postdoctoral research at the Carnegie Institution of Washington Department of Embryology on the steroid-induced gene expression program during tadpole metamorphosis. Rob spent six years as an examiner at the United States Patent and Trademark Office, examining applications in the areas of gene expression and regulation, gene therapy, vectors, and cell lines. He received his J.D. from Georgetown University Law Center and has worked in the patent law field since 1996. Rob is a member of the North Carolina and District of Columbia bars and is registered to practice before the U.S. Patent and Trademark Office. He is a member of the North Carolina Bar Association (NCBA), Association of University Technology Managers, American Intellectual Property Law Association, and American Bar Association. He currently serves as a council member of the NCBA IP Section and has been the chair of the chemistry/biotechnology patents committee. His practice is concentrated in the area of strategic patent counseling and U.S. and foreign patent prosecution in the biotechnological, chemical, and pharmaceutical arts. He is experienced in due diligence, freedom to operate analysis, and invalidity analysis. Before joining Myers Bigel, Rob practiced at an intellectual property firm in Washington, D.C.
